Pharma Major Lupin has received tentative approval for its Pitavastatin Tablets, 1 mg, 2 mg, and 4 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Kowa Company’s Livalo Tablets 1 mg, 2 mg and 4 mg. The filing is from company’s Pithampur (Indore) manufacturing facility.
The company’s Pitavastatin Tablets, 1 mg, 2 mg and 4 mg are the AB rated generic equivalent of Kowa's Livalo Tablets, 1 mg, 2 mg and 4 mg. Pitavastatin Tablets are indicated as an adjunctive therapy to diet to reduce elevated total cholesterol, low-density lipoprotein cholesterol, apolipoprotein B, triglycerides and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia. Livalo Tablets had US sales of $245.3 million as per IMS MAT Sep 2016.
Lupin is a pharmaceutical company and is engaged in formulation of drugs and active pharmaceutical ingredients (APIs), generics, biotechnology, novel drug discovery and development, drug delivery systems and specialty pharmaceuticals.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: